{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T20:37:39Z","timestamp":1726000659997},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/icl.0000000000000004","type":"journal-article","created":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T13:27:23Z","timestamp":1386768443000},"page":"46-50","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of Intralesional Bevacizumab Administration in Primary Pterygium"],"prefix":"10.1097","volume":"40","author":[{"given":"Ozge","family":"Sarac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Demirel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Refik","family":"Oltulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/bjo.2006.091413","article-title":"Pterygium.","volume":"90","author":"Solomon","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ICU.0b013e3281a7ecbb","article-title":"Current concepts and techniques in pterygium treatment.","volume":"18","author":"Ang","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/bjo.67.9.604","article-title":"Histology of pterygium: An electron microscopic study.","volume":"67","author":"Cameron","year":"1983","journal-title":"Br J Ophthalmol"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00055735-199908000-00011","article-title":"The pathogenesis of pterygia.","volume":"10","author":"Coroneo","year":"1999","journal-title":"Curr Opin Ophthalmol"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/bjo.68.5.343","article-title":"Pterygium and ultraviolet radiation: A positive correlation.","volume":"68","author":"Moran","year":"1984","journal-title":"Br J Ophthalmol"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/archopht.1992.01080130101035","article-title":". The long-term effects of visible light on the eye.","volume":"110","author":"Taylor","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00003226-200307000-00015","article-title":". Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia.","volume":"22","author":"Jin","year":"2003","journal-title":"Cornea"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1167\/iovs.05-1130","article-title":"UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling.","volume":"47","author":"Di Girolamo","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/00003226-200110000-00013","article-title":". Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia.","volume":"20","author":"Lee","year":"2001","journal-title":"Cornea"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.ico.0000160971.96447.9e","article-title":"Management of primary pterygia using free conjunctival and limbal-conjunctival autografts without antimetabolites.","volume":"24","author":"Mejia","year":"2005","journal-title":"Cornea"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1136\/bjo.2006.095018","article-title":". Randomised controlled study of conjunctival autograft versus amniotic membrane graft in pterygium excision.","volume":"90","author":"Luanratanakorn","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICO.0b013e31818d382d","article-title":"Effect of subconjunctival bevacizumab on primary pterygium.","volume":"28","author":"Teng","year":"2009","journal-title":"Cornea"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ajo.2005.12.028","article-title":". Conjunctival autografting combined with low-dose mitomycin C for prevention of primary pterygium recurrence.","volume":"141","author":"Frucht-Pery","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ijrobp.2011.06.1988","article-title":". Conjunctival autograft alone or combined with adjuvant beta-radiation A randomized clinical trial.","volume":"82","author":"Viani","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000252980","article-title":". Preliminary results of subconjunctival bevacizumab in primary pterygium excision.","volume":"43","author":"Razeghinejad","year":"2010","journal-title":"Ophthalmic Res"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/IAE.0b013e31822f55de","article-title":". Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.","volume":"32","author":"Soheilian","year":"2012","journal-title":"Retina"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000327364","article-title":". Intracameral injection of bevacizumab for the treatment of neovascular glaucoma.","volume":"226","author":"Wolf","year":"2011","journal-title":"Ophthalmologica"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1542-0124(11)70035-0","article-title":"Anti-VEGF treatment of corneal neovascularization.","volume":"9","author":"Keating","year":"2011","journal-title":"Ocul Surf"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/ICO.0b013e31820ca63f","article-title":". Subconjunctival bevacizumab immediately after excision of primary pterygium: The first clinical trial.","volume":"30","author":"Shenasi","year":"2011","journal-title":"Cornea"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/ICO.0b013e31821c9b44","article-title":". A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: Preliminary results.","volume":"30","author":"Enkvetchakul","year":"2011","journal-title":"Cornea"},{"key":"R24-9-20210128","first-page":"28","article-title":". Multiple subconjunctival bevacizumab for advanced primary pterygium.","volume":"42","author":"Saxena","year":"2010","journal-title":"Ann Ophthalmol (Skokie)"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/ICO.0b013e3181d927b9","article-title":". The effect of subconjunctival ranibizumab on primary pterygium: A pilot study.","volume":"29","author":"Mandalos","year":"2010","journal-title":"Cornea"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ajo.2010.01.015","article-title":". Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery.","volume":"149","author":"Galor","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/sj.eye.6702046","article-title":". Epidemiology of pterygium on a tropical island in the Riau Archipelago.","volume":"20","author":"Tan","year":"2006","journal-title":"Eye (Lond)"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1442-9071.2007.01630.x","article-title":". Pterygium in Tibetans: A population-based study in China.","volume":"35","author":"Lu","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/eye.2008.200","article-title":". Prevalence and risk factors of pterygium and pinguecula: The Tehran Eye Study.","volume":"23","author":"Fotouhi","year":"2009","journal-title":"Eye (Lond)"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/sj.eye.6701917","article-title":"Prevalence of pterygium and cataract in indigenous populations of the Brazilian Amazon rain forest.","volume":"20","author":"Paula","year":"2006","journal-title":"Eye (Lond)"},{"key":"R31-9-20210128","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/ICO.0b013e318151f9c6","article-title":"Liang Xu, Jie Y, et al.. Prevalence of and factors associated with pterygium in adult Chinese. The Beijing Eye Study.","volume":"26","author":"Ma","year":"2007","journal-title":"Cornea"},{"key":"R32-9-20210128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.eye.6703005","article-title":". Pterygium in an aged Mongolian population: A population-based study in China.","volume":"23","author":"Lu","year":"2009","journal-title":"Eye (Lond)"},{"key":"R33-9-20210128","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: Basic science and clinical progress.","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev"},{"key":"R34-9-20210128","first-page":"2115","article-title":". Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes.","volume":"40","author":"Kim","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R35-9-20210128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.mehy.2007.01.047","article-title":"Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia.","volume":"69","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"R36-9-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":". Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"R37-9-20210128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/ICO.0b013e3181e16d67","article-title":". Efficacy of intralesional bevacizumab injection in decreasing pterygium size.","volume":"30","author":"Fallah Tafti","year":"2011","journal-title":"Cornea"},{"key":"R38-9-20210128","first-page":"179","article-title":"Subconjunctival bevacizumab injection in treatment of pterygium.","volume":"49","author":"Besharati","year":"2011","journal-title":"Acta Med Iran"},{"key":"R39-9-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":". Topical bevacizumab in the treatment of corneal neovascularization.","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"}],"container-title":["Eye & Contact Lens: Science & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICL.0000000000000004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:59:10Z","timestamp":1620953950000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00140068-201401000-00009"}},"subtitle":["A Quantitative Analysis"],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/icl.0000000000000004","relation":{},"ISSN":["1542-2321"],"issn-type":[{"value":"1542-2321","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}